Revenue

Former World Bank President Dr. Jim Yong Kim joins ImmunityBio. Is this a new model for biotech social impact or a high-stakes bet on global expansion?

The abrupt exit of President Heather Dixon and the return of a former COO raises critical questions about stability and long-term strategy at the home care giant.

As SKYX Platforms preps its Q2 earnings call, investors look beyond the numbers to its patent moat, e-commerce engine, and leadership's execution strategy.

A new wave of eco-friendly tech is shifting the fight against wildfires from reaction to prevention, forging alliances from fire departments to insurance giants.

Christopher Nolan's 'The Odyssey' has become IMAX's biggest film ever, driving record profits and showcasing groundbreaking camera technology.

Outdoor Holding Company's Q1 results show a stunning recovery. With revenue up 22% and profits secured, its GunBroker platform is outperforming the market.

Revenue missed and its stock plunged, but Quanterix is betting on a new C-suite and its Alzheimer's test to navigate market headwinds and deliver on its promise.

Heron Therapeutics withdraws guidance after a patent blow to its top drug, forcing a strategic review. Can strong growth in new acute care products save it?

Hyosung’s impressive H1 2026 results reveal a shrewd strategy: localizing US power grid production for the AI boom while betting on bio-textiles and humanists.

Amid its pending sale to Zymeworks, Theravance Biopharma’s Q2 results reveal a lesson in resilience, with strong YUPELRI sales and deep cost cuts.

CECO Environmental's record quarter, fueled by a mega-acquisition, reveals a complex story of ambition, financial nuance, and a strategic pivot to dominate.

The work management giant posted strong Q2 results but is betting its future on a radical AI pivot, cutting staff to fund a new era of automated execution.

Strive, Inc. reports a massive Q2 loss on paper, but a closer look reveals a debt-free company doubling down on Bitcoin and launching a daily dividend.

With eight straight quarters of growth, Citi Trends' success isn't just about off-price value. It's a masterclass in strategic focus on a core demographic.

V2X's renewed $500M deal with the Marines goes beyond logistics. It's a story of a 20-year partnership, AI-driven sustainment, and national security.

Amid MENA turmoil, NESR posts a 190% profit surge. A deep dive into the strategy of leveraging specialized services and key contracts to thrive.

With a key leadership hire, UK's Reacta Healthcare leverages its pharma-grade advantage to scale R&D and transform the global food allergy testing landscape.

Beyond the €5.5M price tag, Elis's latest move in Aguascalientes reveals a calculated play for Latin American dominance and the advance of the circular economy.

A new firm is closing the gap between investment and results in the service industry, proving that execution, not just advice, is the ultimate asset.

Amid rising costs, Northview Residential REIT holds firm by refinancing debt, shedding old assets, and doubling down on high-growth Canadian Northern markets.